Lonza Group Ag (OTCMKTS:LZAGY) Sees Large Decline in Short Interest

Lonza Group Ag (OTCMKTS:LZAGY) saw a significant drop in short interest during the month of February. As of February 13th, there was short interest totaling 8,172 shares, a drop of 62.7% from the January 29th total of 21,908 shares. Currently, 0.0% of the shares of the company are sold short. Based on an average daily volume of 428,761 shares, the days-to-cover ratio is presently 0.0 days. Based on an average daily volume of 428,761 shares, the days-to-cover ratio is presently 0.0 days. Currently, 0.0% of the shares of the company are sold short.

Lonza Group Price Performance

LZAGY stock opened at $67.93 on Thursday. Lonza Group has a twelve month low of $55.57 and a twelve month high of $73.85. The company has a debt-to-equity ratio of 0.42, a current ratio of 2.24 and a quick ratio of 1.77. The business’s 50-day simple moving average is $68.40 and its 200 day simple moving average is $68.44.

Analysts Set New Price Targets

LZAGY has been the subject of several recent analyst reports. Royal Bank Of Canada upgraded Lonza Group from a “hold” rating to a “moderate buy” rating in a research note on Wednesday, February 11th. Zacks Research cut Lonza Group from a “hold” rating to a “strong sell” rating in a research report on Wednesday, February 4th. One investment analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. Based on data from MarketBeat, the stock currently has an average rating of “Hold”.

About Lonza Group

Lonza Group is a Swiss multinational life sciences company that provides products and services to the pharmaceutical, biotech and specialty ingredients markets. Headquartered in Switzerland, the company operates globally with manufacturing and research facilities across Europe, North America and Asia, serving customers involved in drug discovery, development and commercial production. Lonza’s client base ranges from large pharmaceutical firms to emerging biotech companies and manufacturers of consumer health and specialty chemical products.

The company’s core activities center on contract development and manufacturing (CDMO) for small molecules and biologics, including process development, clinical and commercial-scale manufacturing, and fill–finish services.